ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received ...

FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has ...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study ...

Pulsetto has announced pricing updates for its compact, non-invasive, vagus nerve stimulation device. Vilnius, Lithuania - August 12, 2024 — Pulsetto is offering a price cut for its wearable device as ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization ...

ROCKAWAY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research ...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject ...

Pulsetto - known for delivering non-invasive, cervical vagus nerve stimulation through a hands-free, app-enabled wearable that promotes stress relief, mental clarity, and sleep support. The links in ...

Chicago, IL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional ...

In 1997, the FDA approved implanted vagus nerve stimulation (VNS) devices as an adjunctive therapy for reducing the frequency and severity of epileptic seizures in pharmaco-resistant epilepsy patients ...